Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Avalo Therapeutics

Request full access

Clinical-stage biotechnology company developing IL-1beta-targeted therapies for immune-mediated inflammatory diseases

Rockville, United StatesFounded 2011Biotech & Life Sciences

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting the IL-1beta (interleukin-1 beta) pathway for immune-mediated inflammatory diseases.The company's lead candidate, abdakibart (AVTX-009), is a humanized monoclonal antibody designed to inhibit IL-1betaand block downstream inflammatory signaling; it is being advanced toward a registrational Phase 3 program following positive Phase 2 results in moderate-to-severe hidradenitis suppurativa,a chronic inflammatory skin condition. Avalo is also developing AVTX-010,a long-acting next-generation anti-IL-1beta monoclonal antibody intended to extend dosing intervals.

The company is based in the United Statesand listed on the Nasdaq under the ticker AVTX.Formed from Cerecor,which changed its name to Avalo Therapeutics in 2021 following its mergerwith Aevi Genomic Medicine,the company shifted away from its earlier neuroscience focus toward immunologyand inflammation.Avalo's business model centers on research and development of novel biologic drug candidates,with eventual commercialization expected through pharmaceutical partnershipsand product sales.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2015
Employees
48
Open positions
None listed
Dealroom signal
91.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Testing, Biotechnology, Neurology, Spinout, Biotech and Pharma, medical testing, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B, B2C
Investment activity
2 companies, latest Mar 2024
Capital deployed
—
Preferred round
ACQUISITION

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing May 2026 $375M — Undisclosed ↗
POST IPO EQUITYOther financing Jun 2025 $75M — Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Avalo Therapeutics website traffic

Latest recorded traffic for Avalo Therapeutics is 2.9K monthly website visits, down 54.7% over the last three months. Avalo Therapeutics's team grew 2.1% over the past year.

Latest monthly visits2.9K 3-month web change-54.7% 1-year team growth+2.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Avalo Therapeutics in the Rockville ecosystem

Live from Dealroom

The Avalo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institute on Drug Abuse (NIDA)

Series A3 investors entered at this stage

  • MPM BioImpact
  • Apple Tree Partners
  • NEA

Series B and later1 investor entered at this stage

  • Horizon Technology Finance Corporation

Other known investors8 additional known investors

Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Rockville HQ
Book a demo for the full country breakdown

See Avalo Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.